Home / Transcripts / IceCure Medical Ltd (ICCM) · August 12, 2026

IceCure Medical Ltd (ICCM) Earnings Call Transcript

August 12, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 34 min

Earnings Call Speaker Segments

Eyal Shamir executive
#1

Thanks, operator, and thanks to all of you for being with us today. For IceCure, the first half of 2026 represents a significant turning point. We have spent the past several years concentrating on establishing the clinical, regulatory, and scientific groundwork for ProSense. We put resources into producing clinical evidence, reaching key regulatory milestones, and educating physicians globally. Now those investments are starting to show up as measurable commercial momentum, even as we keep generating the evidence that underpins future growth. What we think makes this particular phase of our evolution so significant is that our clinical and commercial strategies are no longer moving along separate paths; more and more, each one strengthens the other. As physician adoption grows, it produces additional real-world clinical experience that's broadening both of evidence, boosting physician confidence, supporting future reimbursement efforts, and encouraging wider adoption. The more physicians take up ProSense, the more real-world evidence they generate, forming a self-reinforcing cycle that we expect will keep getting stronger over time. This is precisely the transition we have been aiming for. Revenue for the first half of the year rose roughly 45% compared with the same period a year earlier, reaching $1.8 million, fueled by gains in both ProSense systems and disposable probes. Even more important, this growth shows rising physician adoption and utilization of our technology throughout our commercial install base. A key measure of commercial progress isn't merely how many systems we place, but how often those systems get used. Rising disposable probe sales indicate that physicians are folding ProSense into routine clinical practice and treating more patients as time goes on. This recurring utilization gives us confidence that commercial adoption is becoming broader, deeper, and increasingly sustainable. After FDA clearance for early-stage, low-risk breast cancer, we keep expanding our U.S. commercial footprint, delivering approximately 70% growth in our active U.S. commercial install base. At the same time, we are bolstering our commercial organization with additional sales hires in key U.S. regions, while continuing to grow our presence in select international markets. Our FDA-approved ChoICE post-market study is another important example of how our clinical and commercial strategies are converging. I want to stress an important point about the ChoICE Study. In contrast to a traditional pre-marketing clinical study, the ChoICE trial is a post-market study, it is not separate from our commercialization strategy, rather it is an extension of it. Clinical sites that take part purchase disposable probe as part of routine patient care while at the same time contributing value real-world clinical evidence. Some participating physicians have already moved from clinical investigators into active commercial users of ProSense, while additional leading institutions are joining the study and becoming end users of our technology. This means that clinical evidence generating is supporting commercial adoption, while commercial utilization is simultaneously extending the real-world evidence-supporting process. With more sites coming on board, we anticipate hitting another key short-term goal as the first patients get enrolled into the ChoICE Study. We're still on schedule to carry out the objectives we've laid out, and we're eager to share further updates since the ChoICE Study will keep growing. In our view, the expanding real-world evidence that the ChoICE Study produces, alongside rising commercial uptake, will keep bolstering physician confidence, upcoming reimbursement efforts, and wider market acceptance as time goes on. Past the ChoICE Study, we keep reinforcing the scientific base behind ProSense. In the first six months of 2026, we announced favorable five-year findings from our ICESECRET kidney cancer trial and shared the final data at ECIO 2026. We're also still gaining meaningful recognition from the medical field, such as ProSense being added to the American Society of Breast Surgeons' resource guide, fresh peer-reviewed articles in the International Journal of Surgery and PLOS ONE, and the Society of Interventional Oncology's request to have cryoablation included in the National Comprehensive Cancer Network breast cancer guideline, the NCCN. Beyond the U.S., we keep seeing promising headway in a number of strategic international markets. In Japan, for instance, we keep working constructively with top physicians, medical societies, and strategic partners as we push forward our long-term commercialization work. Although the regulatory path takes time, we stay upbeat about the rising clinical interest and involvement we keep witnessing. Lastly, in the second quarter of 2026, we bolstered our balance sheet even more via our latest financing, closing the first half with roughly $12 million in cash and cash equivalents. That gives us the financial room to keep putting money into commercial growth, physician engagement, generating clinical evidence, and reimbursement efforts as we carry out our long-term growth plan. When I reflect on the first half of 2026, I don't view it as a set of separate milestones. I view it as several distinct signals all pointing the same way. Revenue growth, broader physician adoption, greater disposable probe usage, ongoing clinical recognition, progress on the ChoICE trial, and a stronger financial standing. On their own, each of these accomplishments matters. Taken together, they convey a far larger narrative. They show that IceCure is moving into a new stage of its development, one where commercial execution, clinical leadership, and financial discipline are increasingly aligning to create lasting long-term shareholder value. With that, I'll hand the call over to our Chief Financial Officer, Meir Peleg, who will go over our financial results in more detail.

Meir Peleg executive
#2

Thanks, Eyal. I'll quickly walk through the numbers from our first half of 2026. For that period, revenue rose roughly 45% versus the prior year, reaching $1.8 million, up from $1.25 million a year earlier. The increase came from stronger sales of both ProSense systems and disposable probes. That pickup reflected ongoing commercial expansion as well as rising utilization throughout our commercial installed base. Gross profit for the first half of 2026 came in at $548,000, versus $349,000 during the same stretch last year. Gross margin climbed to 30%, up from 28% a year ago, largely because of greater scale and better operating leverage across our fixed manufacturing and operating cost base as revenue grew. That margin gain would have looked even better once you account for foreign exchange movement during the period, which partly offset the underlying operational improvements. As we keep building commercial scale, our focus stays on balancing investment against disciplined financial management. Through the first half of 2026, we kept putting money into commercial expansion, clinical programs, and organizational capabilities that underpin our long-term growth strategy. R&D expenses totaled $4.3 million in the first half of 2026, compared with $3.4 million in the first half of 2025. That rise was mainly due to kicking off the ChoICE Study, which supports continued clinical expansion of ProSense, plus the effect of foreign exchange fluctuations on our cost structure, which is largely based in Israel. Sales and marketing expenses reached $2.5 million in the first half of 2026, versus $2 million in the first half of 2025. That increase mostly reflects investment in growing our U.S. commercial organization, including extra sales personnel to support rising market activity, physician adoption, and continued expansion of our commercial install base. General and administrative expenses came to $2.4 million in the first half of 2026, compared with $1.9 million in the first half of 2025. That increase was driven mainly by foreign exchange fluctuations affecting payroll-related expenses and by higher non-cash share-based compensation expenses. Net loss for the first half of 2026 was $8.8 million, or $3.17 per share, versus $7 million, or $3.59 per share, in the first half of 2025; we closed the first half of 2026 with roughly $12 million in cash and cash equivalents, compared with $8.9 million at year-end 2025, reflecting financing activities completed during the first half, including about $8.5 million in gross proceeds raised in the second quarter. As always, we stay focused on disciplined capital allocation while backing the commercial, clinical, and regulatory initiatives we believe will drive long-term shareholders' value. With that, operator, we're ready to open the line for questions.

Kemp Dolliver analyst
#3

Hello, everyone, and good day. I'll pose a couple or three questions, then return to the queue. To start, regarding the year-over-year increase in systems revenue, how similar is that revenue when you consider the blend of purchases and leases, given that this could affect how the figures move through the income statement?

Eyal Shamir executive
#4

Meir, please. Hi, Kemp. Eyal here. Meir, could you please take this question.

Meir Peleg executive
#5

Right, absolutely. Regarding what you asked, the bulk of what we bring in is from customers buying new systems outright, not from the leasing arrangements we also offer. That's correct.

Kemp Dolliver analyst
#6

Has the composition shifted when compared with the prior year? That's truly the point I'm getting at.

Eyal Shamir executive
#7

All right, Kemp, I want to make this completely unambiguous. Your question was whether the purchase system — particularly within the U.S. — rose versus the same period a year ago, so it could be set against the placement. Is that what you're asking?

Kemp Dolliver analyst
#8

OK, yes, that's a different perspective on what we're asking.

Eyal Shamir executive
#9

Right. To start, the share for disposable items hasn't changed, though use of our single-use probe went up slightly compared with a year earlier; there might be room for greater use, yet essentially it stayed flat with SunProbes, and we can expect that, particularly regarding upcoming post-market studies, which will run alongside commercialization efforts, since every site taking part in a study will also be a commercial site. We're seeing more consoles bought outright rather than simply placed at a special price, a higher price, and it's quite encouraging that sites are ready to purchase the console, treating it as a new treatment and a new technology within the future commercialization offering, while also joining the study. Growth on both fronts looks likely.

Meir Peleg executive
#10

Right, so perhaps I can give you a bit more detail here. If we look at the first six months of 2026 versus the opening half of 2025, the number of systems we moved rose by roughly 20% to 25% when expressed as a percentage, even though the placement figure stayed flat. When you look at it in percentage terms, the placement — or lease, whatever term you prefer — represents a smaller share this year relative to last year than sales do.

Kemp Dolliver analyst
#11

All right, that's helpful. What does your U.S. installed base look like at this point?

Eyal Shamir executive
#12

Once again, since we achieved a 70% rise in our active units, that figure has climbed. In the U.S., the number of active sites sits near 30, Gabi.

Kemp Dolliver analyst
#13

Was that 30 — three zero?

Eyal Shamir executive
#14

Not at all. Altogether, the total is over 30, three zero, sites.

Kemp Dolliver analyst
#15

All right. Thanks. That covers everything on my end.

Anthony Vendetti analyst
#16

Yes, thank you. Let me make sure I understand — commercial footprint was up 70%. How many active commercial installations are there? Did you already provide that figure? I missed it.

Eyal Shamir executive
#17

No, we simply noted — in case you recall back in June — that following the FDA decision in October of last year, we've seen a 70% increase in active sites.

Anthony Vendetti analyst
#18

All right, so how many active commercial sites does that figure cover — as of the 30th of June, or as of right now?

Eyal Shamir executive
#19

The count sits above 30, since a portion of those sites won't take part. Those locations are simply going to keep using it commercially and nothing more, which is what we told everyone about a few of them during the past six months — or perhaps even longer-standing, very strong accounts, including some console accounts that will keep handling a large volume of cases yet won't be included in the PMS.

Anthony Vendetti analyst
#20

Regarding the clinical side of things — how many clinical sites are there right now, or as of June 30th?

Eyal Shamir executive
#21

We currently have more than 10 underway. We've announced the initial 2, for which we hold a signed contract and IRB approval; each week, additional sites are at various stages of settling the budget, the contract, and IRB approval. Site number 3 should follow the first 2 very shortly, and we anticipate the initial patients within 3 to 4 weeks.

Anthony Vendetti analyst
#22

All right. So you've flagged over 10 that you're engaged with, yet 2 have completed the entire IRB approval path and executed the agreement, and you anticipate dosing the initial patient within 3 to 4 weeks. Did I get that right?

Eyal Shamir executive
#23

Yes, precisely, Anthony.

Anthony Vendetti analyst
#24

All right, that's great. Regarding the gross margin for this quarter, it came in somewhat below what was anticipated. Did that include certain possibly non-recurring expenses, or did it simply reflect the product mix between probes and system sales?

Eyal Shamir executive
#25

Two factors are at play here. As you noted, a mix shift exists, though I'd characterize it as small. The primary factor behind our not achieving a considerably greater gross margin, which we expected given the stronger top line, stems largely from currency rate movements. Right? Had we applied an identical currency rate — I'm referring to the shekel versus the US dollar — as we did a year ago, gross margin would have been significantly greater at double digits compared with now.

Anthony Vendetti analyst
#26

All right. Understood. Actually, yesterday we had a conversation with a business based in Israel, and their account matched this one; according to them, currency movement involving the shekel and the US dollar hit them during this quarter too. Fine. Now, regarding obtaining those additional ones — so there are 2 currently active that have already been through the entire procedure. The IRB approval, I realize the schedule for that can be somewhat tricky, but roughly how much time is needed for every hospital to secure it? Is a minimum of a month required? Might it stretch beyond 3 months? I realize this process is somewhat unpleasant, but I'm simply attempting to grasp how the timing works.

Eyal Shamir executive
#27

Yes. Shay, our COO, is going to respond to that.

Shay Levav executive
#28

Yes. Eyal, thanks. Anthony, hello there.

Anthony Vendetti analyst
#29

Shay.

Shay Levav executive
#30

Certain locations rely on a central IRB — that route is considerably easier and might require three to four or to five weeks — while others go through their own IRB, which can run somewhat longer, four to six to seven weeks; roughly speaking, that's the IRB timeline.

Anthony Vendetti analyst
#31

Alright. When it comes to the post-market study, looking at your current position, are you still confident about reaching the required hurdle rates regarding the number of patients treated, the way it's laid out by

Eyal Shamir executive
#32

Yes, we have strong confidence that we can meet it; the initial patients need to be enrolled before September 5. That's the reason I noted we anticipate the first patient being enrolled. In fact, according to the FDA definition it's enrolled, not even treated; we're aware that of the two sites, one belongs to Dr. Richard Fine, a former president of the society, and he handled 51 cases as part of IceCure, a very experienced site. We paid them a visit earlier this week; they are completely prepared. They've got some patients on the list. The same goes for Dr. Dennis Holmes. As a concierge breast surgeon, he's doing the largest number in the U.S.; so we're confident they will get it done. Together with Dr. Nathalie Johnson, who was also a president of the society, she'll be at one of the upcoming sites, and so on. We're confident we'll also be able to reach the 80 patients by March 2027.

Anthony Vendetti analyst
#33

All right, that's really helpful. I appreciate the detail. I'll get back in line.

Eyal Shamir executive
#34

Thanks.

Scott Henry analyst
#35

Thanks, and good morning or good afternoon, wherever you happen to be. Two questions. First, during the previous conference call, you said the CPT Category I reimbursement code would be filed in mid-June. Could you share any updates about that, and what would come next in expanding that reimbursement? Thanks.

Eyal Shamir executive
#36

Thanks so much, Henry. Because of the AMA compliance and confidential clause, which are extremely strict, I'm unable to either confirm or deny anything regarding the submission. What I can say is that our plan is moving forward just as we talked about. The AMA does not permit announcing it, and we haven't seen any other publicly traded company that made a submission public; so we must comply so as not to take on risk, but our plan continues to progress.

Scott Henry analyst
#37

Understood, that's reasonable. Suppose someone went ahead and filed the CPT Category I code — what happens after that? Would there be a period during which they seek comments, or would they put something out? When should we look for our following data point?

Eyal Shamir executive
#38

One of your peers told us that they personally observed on the AMA website, which anyone can access, that breast cancer cryoablation appears on the upcoming agenda for the AMA meeting, anticipated for the second or third weekend of September; anybody can view this. Once more, we are not in a position to make an announcement.

Scott Henry analyst
#39

Alright, that's helpful context. Turning to revenues, it seems both Q1 and Q2 came in at a somewhat elevated level, roughly $900,000 give or take. What's the right way to frame the back half of 2026? Should we be looking for an inflection point in Q4, or rather steady improvement across Q3? I'm just attempting to understand the trajectory, taking into account seasonality and any other factors that could affect it. Thanks.

Meir Peleg executive
#40

Eyal, would you like me to take that one, or would you prefer to?

Eyal Shamir executive
#41

Of course — Meir, the floor is yours.

Meir Peleg executive
#42

Right. We aren't providing any guidance about future periods. Still, it's worth keeping in mind that the third quarter typically comes in weaker than the rest of the year, since that's when people take holidays all over the globe, or at minimum across the northern hemisphere. Our peak quarter annually tends to be the fourth. Given that, plus the expansion we delivered during the first half, you can roughly estimate what our second-half results will look like.

Scott Henry analyst
#43

All right, excellent. I appreciate that context. Last item from me, and it's somewhat more targeted. Regarding the count of shares outstanding, is it right to anticipate — I looked at portions of the documents filed today, though I haven't reviewed all of them completely, and it appears a substantial number of pre-funded warrants showed up, roughly 1.2 million. Is it right to anticipate those adding to shares outstanding for Q3?

Eyal Shamir executive
#44

Meir?

Meir Peleg executive
#45

Could you say that again? The question is whether we ought to anticipate the remainder of those pre-funded warrants.

Scott Henry analyst
#46

On the pre-funded warrant accounting, it appeared that a large number went through during July and August. Would all of that simply add to shares outstanding, or has part of it already been included?

Meir Peleg executive
#47

A portion of those had already been included.

Scott Henry analyst
#48

Okay, alright. I'll address that in a separate discussion, then. Thanks for taking my question.

Eyal Shamir executive
#49

Thanks for being with us today, and for the ongoing interest you've shown in IceCure. Looking forward, our priorities haven't changed and they're quite clear. To begin with, we'll keep expanding our commercial reach through more physician adoptions, higher procedure volume, and better utilization throughout our installed base. Next, we'll keep carrying out the ChoICE Study, bringing on more top clinical sites, and starting patient enrollment as we move that study forward as planned. It's important to note that we regard the ChoICE Study as far more than just a clinical study — it's a key piece of our wider commercialization strategy, built to produce real-world evidence while backing physician adoption and future reimbursement opportunity. Third, we'll keep reinforcing the scientific and clinical groundwork behind ProSense via ongoing investigator-led research, peer-reviewed publication, medical societies engagement, and steady collaboration with key opinion leaders globally; we're also staying focused on pushing forward our long-term international opportunities, Japan included, where engagement from physician medical societies and strategic partners continues to look encouraging. Looking at the business right now, we think the key takeaway isn't some individual milestone, but rather how the business keeps evolving. Commercial adoption is backing clinical evidence, and clinical evidence is boosting physician confidence. Rising physician confidence is widening commercial adoption. We believe this builds a powerful, sustainable foundation for our long-term goals; we're still early in our commercial journey, yet the progress we're making encourages us, as does the growing number of independent indicators validating our strategy. On behalf of everyone at IceCure, thank you for your ongoing support and confidence. We look forward to updating you on our continued progress throughout the remaining of the year.

Operator operator
#50

That wraps up the conference call on IceCure's results for the first half of 2026. We appreciate everyone for joining. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete IceCure Medical Ltd transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to IceCure Medical Ltd earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.